PD-L1 testing in lung cancer — what your score actually means

No. Most people diagnosed with lung cancer in India do not receive immunotherapy. A targetable driver mutation, active autoimmune disease, ongoing high-dose steroids, an organ transplant, poor performance status, or tissue that cannot be scored will each take it off the table. PD-L1 testing is one gate among several, and it is not the first one.

That matters before you read another line about your score. A high PD-L1 number is not permission to start immunotherapy, and a low one is not a verdict. The number sits inside a checklist your team works through in order. Here is what usually settles the question first.

• A targetable driver mutation — an EGFR, ALK or ROS1 change means the matching targeted tablet comes first. These mutations are common in Indian patients, especially in adenocarcinoma and in people who never smoked.
• Active autoimmune disease or immunosuppression — a poorly controlled autoimmune condition, or an organ transplant on anti-rejection medicines, usually makes checkpoint immunotherapy unsafe.
• Steroids at the start — a meaningful daily steroid dose taken for another medical reason can work against the way immunotherapy is meant to act.
• General fitness — patients who are bed-bound or need substantial help with daily activities are often unsuitable for any systemic treatment.
• No scoreable tissue — a fluid or fine-needle sample can hold too few tumour cells for a score to be issued at all.
• The cancer subtype — PD-L1 guides non-small cell lung cancer. In small cell disease, immunotherapy decisions do not turn on a PD-L1 number.

PD-L1 testing for CION patients is coordinated through accredited partner pathology laboratories, which perform the staining and the scoring. Immunotherapy itself, when it is appropriate, is given as a day-care infusion at CION centres.

Bands reflect the TPS thresholds used in NCCN and ESMO non-small cell lung cancer guidance, indicative as of August 2026, and apply to advanced non-small cell disease without a targetable driver mutation. Early-stage, operable and small cell lung cancer follow different rules. This table is general education, not a statement about your own eligibility.

At a TPS of 50% or above, immunotherapy on its own — without chemotherapy — becomes a recognised first-line option to discuss for advanced non-small cell lung cancer. Below 50%, that single-agent route is not the standard path, and the usual discussion is chemotherapy given together with immunotherapy.

This is the one place where the number rewrites the regimen rather than adding context. It is also where patients most often over-read it. Crossing 50% opens a door; it does not push you through it. A high score with fast-moving disease, heavy symptoms or a large tumour burden may still lead a tumour board to advise the combination, because chemotherapy tends to act faster. What gets weighed alongside the score:

• How fast the disease is moving — rapid progression or heavy symptoms often favours starting with a combination.
• Tumour burden and spread — organ-threatening disease changes how much time there is to wait for a response.
• Fitness and other illnesses — kidney and heart function, diabetes, prior lung disease and performance status all shape what can safely be given.
• Tolerance for chemotherapy — for some patients avoiding it is the point of a high score; for others the trade-off runs the other way.
• Autoimmune history — thyroid, bowel or joint autoimmune disease raises the risk of immune-related side effects.
• The option of not starting — where fitness is poor or the burden of travel and infusions outweighs the likely gain, best supportive care is a real choice.

One caveat to carry into that conversation: a TPS result is not a prediction. It shifts the odds that an approach helps. It does not tell any individual patient what will happen to them.

A TPS of zero means no tumour cells on the tissue that was tested showed PD-L1 staining. It does not remove immunotherapy from the plan. In advanced non-small cell lung cancer, immunotherapy is still commonly considered for PD-L1-negative patients — as part of a combination with chemotherapy rather than on its own.

Zero is also the score most worth questioning before it is accepted as final. PD-L1 is not spread evenly through a tumour, so a small biopsy can miss positive areas. Stored blocks lose staining quality over time. Treatment given between the biopsy and the test can alter expression. If the result does not fit your clinical picture, ask whether a fresher sample should be tested.

What a zero score should not trigger is a hunt for a replacement. Chemotherapy, targeted treatment where a driver mutation exists, radiation and surgery remain the same options they were before the result arrived. The score changes which immunotherapy conversation you have, not the rest of the plan.

• EGFR — the most frequently found targetable change in Indian adenocarcinoma patients, and a common reason a high PD-L1 score does not lead to immunotherapy first.
• ALK and ROS1 rearrangements — less common than EGFR, similarly decisive, and similarly treated with targeted tablets first.
• Other actionable alterations — BRAF, KRAS, MET, RET and NTRK are checked on broader panels and can each change the plan.
• Histology subtype — adenocarcinoma, squamous or small cell, confirmed before the biomarker questions are asked, because small cell disease follows a different route.
• Staging imaging — a PET-CT or CT defines how far the disease has spread. Response-assessment PET-CT for CION patients is coordinated at partner imaging centres.
• Baseline organ and immune checks — thyroid, liver, kidney and blood counts, plus a careful autoimmune history.

Where tissue is limited, the order in which tests are requested matters, so the sample is not exhausted before the results that change the plan come back.

1. 1

   Your existing tissue block is located

   The paraffin block from your diagnostic biopsy or surgery is retrieved. A fresh biopsy is arranged only when that sample is too small or too degraded to score.

2. 2

   Immunohistochemistry staining is performed

   Thin sections are stained with a validated PD-L1 assay at an accredited partner pathology laboratory. CION coordinates the referral; the staining is not done in-house.

3. 3

   A pathologist counts and reports the TPS

   Stained tumour cells are counted against total viable tumour cells and issued as the TPS. Turnaround is commonly around a week for PD-L1 alone, longer with a wider molecular panel.

4. 4

   The tumour board reads it in context

   Medical, surgical and radiation oncologists read the band alongside your molecular results, staging and general health, then explain the plan in a 45-minute consultation.

• Immunotherapy Alone or With Chemotherapy for Lung Cancer? — the decision a TPS of 50% or above actually opens up, walked through in full.
• EGFR and ALK Mutations: Why Immunotherapy May Not Be for You — read this before acting on a high PD-L1 score, because a driver mutation changes the answer.
• PD-L1 Score: TPS vs CPS Explained — why lung cancer is scored with TPS while several other cancers use CPS, and why the numbers are not comparable.
• Pneumonitis Risk in Lung Cancer Patients on Immunotherapy — the lung-specific side effect to understand before you start, and the warning signs that need a same-day call.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is planned, given as day care and monitored across CION centres.

This page explains PD-L1 scoring in lung cancer for general education. It does not interpret any individual report or recommend any specific medicine. Cut-offs reflect NCCN and ESMO non-small cell lung cancer guidance, indicative as of August 2026, and guidelines are revised periodically. PD-L1 testing is coordinated at accredited partner pathology laboratories.

One consultation, one clear answer on where you stand

Forty-five minutes with a medical oncologist who explains the score, the missing tests and the honest options — including the option of not starting immunotherapy at all.